Refractory Acute Myeloid Leukemia Clinical Trials in Columbus, Ohio

4 studies are recruiting for refractory acute myeloid leukemia in Columbus, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

   This phase II trial studies the side effects and how well Vyxeos works in treating patients with intermediate and high-risk acute myeloid leukemia who have failed an initial cycle of standard cytarabine and daunorubicin chemotherapy. Vyxeos is a combination of both chemotherapy drugs cytarabine and…

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Locations

   2 in total

   Run by

   Ohio State University Comprehensive Cancer Center

   See if you can join NCT04049539 on ClinicalTrials.gov

2. Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

   This phase I trial studies the side effects and best dose of ruxolitinib when given together with venetoclax and compares the effect of ruxolitinib in combination with venetoclax to venetoclax and azacitidine in treating patients with acute myeloid leukemia (AML) that has come back (relapsed) or ha…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Locations

   3 in total

   Run by

   Jennifer Saultz

   See if you can join NCT03874052 on ClinicalTrials.gov

3. SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

   This phase I trial tests the safety, side effects, and best dose of SNDX-5613 and gilteritinib for treating patients with acute myeloid leukemia that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory) and has a mutation in the FLT3 gene along w…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Locations

   4 in total

   Run by

   Uma Borate

   See if you can join NCT06222580 on ClinicalTrials.gov

4. A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

   Study BH-30236-01 is a first-in-human (FIH), Phase 1/1b, open-label, dose escalation and expansion study in participants with relapsed/refractory acute myelogenous leukemia (R/R AML) or higher-risk myelodysplastic syndrome (HR-MDS). Phase 1, Part 1 Dose Escalation - Monotherapy will evaluate the sa…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Ohio State University Wexner Medical Center - James Cancer Hosp, Columbus, Ohio

   Locations

   13 in total

   Run by

   BlossomHill Therapeutics

   See if you can join NCT06501196 on ClinicalTrials.gov